CEO Virginia Burger (New Equilibrium Biosciences)

Bet­ting ear­ly on an AI niche, RA Cap­i­tal seeds a young founder's quest to un­lock 'Holy Grail' tar­gets

Ar­ti­fi­cial in­tel­li­gence, with its grandiose claims and sweep­ing promis­es to rev­o­lu­tion­ize drug dis­cov­ery, may seem om­nipresent in bio­phar­ma now. But Vir­ginia Burg­er and RA Cap­i­tal be­lieve there are nich­es it has yet to touch.

Af­ter tak­ing up res­i­den­cy at the star-stud­ded Boston ac­cel­er­a­tor Petri, Burg­er’s start­up — named New Equi­lib­ri­um Bio­sciences — has scored $10 mil­lion in seed cash from the VC firm to prove that by reach­ing in­to those cor­ners, they could un­cov­er drugs against “Holy Grail” tar­gets in every­thing from can­cer to neu­rode­gen­er­a­tive dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.